DSpace Repository :: Browsing by Author "Paredes, Roger"

Now showing 1 - 1 of 1

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Human Immunodeficiency Virus Type 1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
(Oxford University Press, 2025-03-13) Rockstroh, Jürgen K.; Paredes, Roger; Cahn, Pedro; Molina, Jean-Michel; Sokhela, Simiso M.; Hinestrosa, Federico; Kassim, Sheetal; Cunningham, Douglas; Ghosn, Jade; Bogner, Johannes R.; Gatanaga, Hiroyuki; Asante-Appiah, Ernest; Zhang, Ying; Nwoke, Uchechukwu; Klopfer, Stephanie O.; Eves, Karen; Squires, Kathleen; Correll, Todd; Fox, Michelle C.; Pisculli, Mary L.
Background Doravirine/islatravir is an investigational regimen that is being studied for human immunodeficiency virus type 1 (HIV-1) treatment. Methods In this phase 3, double-blind, double-dummy trial (ClinicalTrials.gov NCT04233879), previously untreated adults with HIV-1 were randomized (1:1) and stratified by HIV-1 RNA (≤/>100 000 copies/mL) and CD4 count (